Search

Your search keyword '"Prica, Anca"' showing total 13 results
Start Over Author "Prica, Anca" Journal leukemia & lymphoma
13 results on '"Prica, Anca"'

4. Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy

Author

Liu, Jiajia, primary, Stewart, Douglas, additional, Fontaine, Amelie, additional, Peters, Anthea, additional, Fleury, Isabelle, additional, Mollica, Luigina, additional, Prica, Anca, additional, Buckstein, Rena, additional, Sehn, Laurie, additional, Jiang, Aixiang, additional, Kuruvilla, John, additional, and Villa, Diego, additional

Published
2020
Full Text
View/download PDF

6. An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment – validation of official dosing guidelines

Author

Chen, Christine I., primary, Cao, Yanshuo, additional, Trudel, Suzanne, additional, Reece, Donna E., additional, Kukreti, Vishal, additional, Tiedemann, Rodger, additional, Prica, Anca, additional, Paul, Harminder, additional, Le, Lisa W., additional, Levina, Olga, additional, Kakar, Sumeet, additional, Lau, Anthea, additional, Chen, Hongzhuan, additional, and Chen, Eric, additional

Published
2020
Full Text
View/download PDF

7. IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia

Author

Assouline, Sarit, primary, Amrein, Lilian, additional, Aloyz, Raquel, additional, Banerji, Versha, additional, Caplan, Stephen, additional, Owen, Carolyn, additional, Hasegawa, Wanda, additional, Robinson, Sue, additional, Shivakumar, Sudeep, additional, Prica, Anca, additional, Peters, Anthea, additional, Hagerman, Linda, additional, Rodriguez, Laura, additional, Skamene, Tanya, additional, Panasci, Lawrence, additional, Chen, Bingshu E., additional, and Hay, Annette E., additional

Published
2020
Full Text
View/download PDF

11. Significance of treatment response when managing patients with primary central nervous system lymphoma.

Author

Chan, Henry, Crump, Michael, Kuruvilla, John, Moraes, Fabio Ynoe, Berlin, Alejandro, Laperriere, Normand, Mason, Warren, and Prica, Anca

Subjects
CENTRAL nervous system, PROGRESSION-free survival, RADIOTHERAPY
Abstract

The precise role of radiation therapy in primary central nervous system lymphoma (PCNSL) remains controversial. We reviewed the records of all patients treated for PCNSL at our center between 2004 and 2015. A total of 103 patients treated with either chemotherapy alone (n = 30), radiotherapy alone (n = 36), or combined-modality treatment (n = 37) were analyzed. The median progression-free survival (PFS) and overall survival (OS) were 13.9 and 20.9 months, respectively. Of those who received chemotherapy, 52.2% achieved complete response/ unconfirmed complete response (CR/Cru) after induction; a trend for improved PFS was observed for those who received consolidation WBRT (NR vs. 30.1 months, p = .092) but not OS (NR vs. 31.6 months, p = .283). Patients who achieved a partial response with chemotherapy and proceeded with WBRT had a similar long-term survival to those who achieved CR/CRu with chemotherapy without WBRT (PFS 15.2 vs. 30.1 months, p = .888; OS 22.0 vs. 31.6 months, p = .340). Consolidation WBRT improved PFS, but not OS, and this must be balanced against possible risks of neurotoxicity. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

13. Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the NCIC-CTG LY.12 clinical trial.

Author

Vijenthira, Abi, Li, Xinzhi, Crump, Michael, Hay, Annette E., Shepherd, Lois, Meyer, Ralph M., Djurfeldt, Marina, Chen, Bingshu E., and Prica, Anca

Subjects
*CLINICAL trials, *FRAILTY, *SECONDARY analysis, *LYMPHOMAS, *STEM cell transplantation
Abstract

AbstractThe prevalence of frailty in clinical trials of lymphoma is unknown. We conducted a secondary analysis of the phase III LY.12 trial in which patients with relapsed aggressive non-Hodgkin lymphoma were randomized to different salvage regimens before autologous stem cell transplant. The primary objective was to construct a lymphoma clinical trials-specific frailty index (LyFI) using previously described methods. The secondary objective was to describe the association of frailty withover all and event-free survival (OS, EFS). The LyFI was constructed using 619 patients, and11% (N = 70) were classified as frail. Frailty was associated with EFS (HR 1.94, 95%CI 1.53–2.46) and OS (HR 2.01, 95%CI 1.57–2.58) in univariable analysis, but was only significant as a continuous (not binary) variable in multivariable analysis controlling for prognostic score, suggesting limitations of a FI in this trial population. Future work could validate the FI using clinical assessments and/or apply it to an older trial population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results